Code Biotherapeutics, Inc.

10:45 AM - 11:00 AM (EDT), Tuesday, June 6, 2023 ・ Session Room 103
Code Bio is developing transformational, non-viral, genetic medicines to treat and potentially cure serious and life-threatening diseases. Pioneering targeted delivery of genetic medicines, Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity.

The Company is advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne’s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chairman, Chief Executive Officer, and Co-Founder
Code Biotherapeutics